The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study
- PMID: 36529829
- PMCID: PMC9760540
- DOI: 10.1186/s40352-022-00199-1
The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study
Abstract
While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed protocols to sustain healthcare delivery while reducing risk of COVID-19 transmission. This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. In December 2020, carceral sites (n = 6; median pre-COVID 2020 monthly census = 3468 people) and CTPs (n = 7; median pre-COVID 2020 monthly census = 550 patients) participating in EXIT-CJS completed a cross-sectional web-based survey. The survey assessed changes pre- (January-March 2020) and post- (April-September 2020) COVID-19 in OUD treatment, telemedicine use, re-entry supports and referral practices. Compared to January-March 2020, half of carceral sites (n = 3) increased the total number of persons initiating medication for opioid use disorder (MOUD) from April-September 2020, while a third (n = 2) decreased the number of persons initiated. Most CTPs (n = 4) reported a decrease in the number of new admissions from April-September 2020, with two programs stopping or pausing MOUD programs due to COVID-19. All carceral sites with pre-COVID telemedicine use (n = 5) increased or maintained telemedicine use, and all CTPs providing MOUD (n = 6) increased telemedicine use. While expansion of telemedicine services supported MOUD service delivery, the majority of sites experienced challenges providing community support post-release, including referrals to housing, employment, and transportation services. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to continue delivery of treatment for OUD. Expansion of telemedicine services was critical to support MOUD service delivery. Despite these innovations, sites experienced challenges providing reintegration supports for persons in the community. Pre-COVID strategies for identifying and engaging individuals while incarcerated may be less effective since the pandemic. In addition to expanding research on the most effective telemedicine practices for carceral settings, research exploring strategies to expand housing and employment support during reintegration are critical.
Keywords: Buprenorphine; COVID-19; Carceral settings; Medication for opioid use disorder (MOUD); Naltrexone; Opioid use disorder.
© 2022. The Author(s).
Conflict of interest statement
Drs. Lee, Springer, Farabee, and Waddell have received in-kind study drug from Indivior and Alkermes for other federally funded trials. Dr. Springer has provided scientific consultation for Alkermes. Dr. Schwartz has provided consultation for Verily Life Sciences. Dr. Marsch is affiliated with Pear Therapeutics, Inc. and Square2 Systems, Inc. Dr. Gryczynski is part owner of COG Analytics. Drs. Gryczynski, Lee, and Monico have received research funding from Indivior for conduct of a health survey study.
Similar articles
-
COVID-19 and treating incarcerated populations for opioid use disorder.J Subst Abuse Treat. 2021 May;124:108216. doi: 10.1016/j.jsat.2020.108216. Epub 2020 Dec 2. J Subst Abuse Treat. 2021. PMID: 33288348 Free PMC article.
-
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284. JAMA Psychiatry. 2022. PMID: 36044198 Free PMC article.
-
Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.Addict Sci Clin Pract. 2022 Jun 2;17(1):30. doi: 10.1186/s13722-022-00313-6. Addict Sci Clin Pract. 2022. PMID: 35655293 Free PMC article.
-
Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.Addict Sci Clin Pract. 2021 Nov 13;16(1):68. doi: 10.1186/s13722-021-00275-1. Addict Sci Clin Pract. 2021. PMID: 34774106 Free PMC article. Review.
-
Opioid treatment programs, telemedicine and COVID-19: A scoping review.Subst Abus. 2022;43(1):539-546. doi: 10.1080/08897077.2021.1967836. Epub 2021 Sep 14. Subst Abus. 2022. PMID: 34520702 Review.
References
-
- 117th Congress . H.R.955 - Medicaid reentry act of 2021. 2021.
-
- 117th Congress . Humane correctional health care act. 2021.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous